Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Xenon Pharmaceuticals Inc
XENECurrent price
30.29 USD
+0.62 USD (+2.09%)
Last closed
29.57 USD
Company
www.xenon-pharma.com
ISIN
CA98420N1050
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 269 012 480 USD
Yield for 12 month
-23.89 %
1Y
3Y
5Y
10Y
15Y
XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Address: 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
55.12 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
+7 500 000 USD
Last Quarter
–
Current Year
–
Last Year
-167 512 000 USD
Current Quarter
–
Last Quarter
–
Key Figures XENE
1 year
3 years
5 years
10 years
EBITDA
-276 737 984 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-19.80 %
PEG Ratio
-0.060
Return On Equity TTM
-27.85 %
Wall Street Target Price
55.12 USD
Revenue TTM
–
Book Value
9.88 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
-210 394 000 USD
Earnings per share
-3.22 USD
Diluted Eps TTM
-3.22 USD
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics XENE
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History XENE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation XENE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
230.41
Price Sales TTM
308.19
Enterprise Value EBITDA
-11.81
Price Book MRQ
3.22
Financials XENE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators XENE
For 52 weeks
26.74 USD
46.00 USD
50 Day MA
34.44 USD
Shares Short Prior Month
3 970 374
200 Day MA
38.87 USD
Short Ratio
3.78
Shares Short
3 584 868
Short Percent
5.22 %
BeatStart